Integrin-mediated cancer progression as a specific target in clinical therapy

This publication has 138 references indexed in Scilit:

• Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways
  Oncogene, 2012
• Expression of αV-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti – αV-Integrin Antibody
  International Journal of Gynecological Cancer, 2011
• A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma
  British Journal of Cancer, 2011
• Targeting tumor cell motility to prevent metastasis
  Advanced Drug Delivery Reviews, 2011
• Integrin Structure, Activation, and Interactions
  Cold Spring Harbor Perspectives in Biology, 2011
• Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
  Investigational New Drugs, 2010
• Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
  Clinical Cancer Research, 2008
• Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
  British Journal of Cancer, 2006
• Integrins
  Cell, 2002
• Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins
  Nature Medicine, 2002